Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma

M. Jim Yen, Chih Yi Hsu, Tsui Lien Mao, Tzyy Choou Wu, Richard S Roden, Tian-Li Wang, Ie Ming Shih

Research output: Contribution to journalArticle

Abstract

Purpose: Mesothelin is an emerging marker for cancer diagnosis and target-based therapy, yet relatively little is known about the clinical significance of mesothelin expression in tumors. In this study, we correlate mesothelin immunoreactivity to clinicopathologic features in ovarian serous carcinoma. Experimental Design: Mesothelin expression levels were compared among 81 publicly available serial analysis of gene expression (SAGE) libraries of various carcinoma and normal tissue types. Immunohistochemistry using a well-characterized mesothelin monoclonal antibody (5B2) was done to evaluate mesothelin expression in 167 high-grade and 31 low-grade ovarian serous carcinomas. Immunohistochemistry staining scores were correlated with patient survival, tumor site, tumor grade, in vitro drug resistance, and differentiation status of tumor cells. Results: SAGE analysis showed that mesothelin was overexpressed in 50% of ovarian and pancreatic carcinomas but rarely in other cancer types, including liver, colon, kidney, prostate, and breast. Mesothelin immunoreactivity (>5% of tumor cells) was present in 55% of ovarian serous carcinomas with no difference in expression between high-grade and low-grade serous tumors (P = 0.82). Based on Kaplan-Meier analysis, we found that a diffuse mesothelin staining (>50% of tumor cells) in primary high-grade ovarian carcinomas correlated significantly with prolonged survival in patients who had advanced-stage disease and had received optimal debulking surgery followed by chemotherapy (P = 0.023). Mesothelin expression did not correlate significantly with patient age, tumor site, in vitro drug resistance, or tumor differentiation status (P > 0.10). Conclusion: Our results provided new evidence that mesothelin expression is associated with prolonged survival in patients with high-grade ovarian serous carcinoma.

Original languageEnglish (US)
Pages (from-to)827-831
Number of pages5
JournalClinical Cancer Research
Volume12
Issue number3 I
DOIs
StatePublished - Feb 1 2006

Fingerprint

Carcinoma
Survival
Neoplasms
Drug Resistance
mesothelin
Immunohistochemistry
Staining and Labeling
Gene Expression
Kaplan-Meier Estimate
Liver Neoplasms
Gene Library
Prostate
Colon
Breast
Research Design
Monoclonal Antibodies
Kidney
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. / Yen, M. Jim; Hsu, Chih Yi; Mao, Tsui Lien; Wu, Tzyy Choou; Roden, Richard S; Wang, Tian-Li; Shih, Ie Ming.

In: Clinical Cancer Research, Vol. 12, No. 3 I, 01.02.2006, p. 827-831.

Research output: Contribution to journalArticle

@article{b9770583c9ff48eca5c832b126069589,
title = "Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma",
abstract = "Purpose: Mesothelin is an emerging marker for cancer diagnosis and target-based therapy, yet relatively little is known about the clinical significance of mesothelin expression in tumors. In this study, we correlate mesothelin immunoreactivity to clinicopathologic features in ovarian serous carcinoma. Experimental Design: Mesothelin expression levels were compared among 81 publicly available serial analysis of gene expression (SAGE) libraries of various carcinoma and normal tissue types. Immunohistochemistry using a well-characterized mesothelin monoclonal antibody (5B2) was done to evaluate mesothelin expression in 167 high-grade and 31 low-grade ovarian serous carcinomas. Immunohistochemistry staining scores were correlated with patient survival, tumor site, tumor grade, in vitro drug resistance, and differentiation status of tumor cells. Results: SAGE analysis showed that mesothelin was overexpressed in 50{\%} of ovarian and pancreatic carcinomas but rarely in other cancer types, including liver, colon, kidney, prostate, and breast. Mesothelin immunoreactivity (>5{\%} of tumor cells) was present in 55{\%} of ovarian serous carcinomas with no difference in expression between high-grade and low-grade serous tumors (P = 0.82). Based on Kaplan-Meier analysis, we found that a diffuse mesothelin staining (>50{\%} of tumor cells) in primary high-grade ovarian carcinomas correlated significantly with prolonged survival in patients who had advanced-stage disease and had received optimal debulking surgery followed by chemotherapy (P = 0.023). Mesothelin expression did not correlate significantly with patient age, tumor site, in vitro drug resistance, or tumor differentiation status (P > 0.10). Conclusion: Our results provided new evidence that mesothelin expression is associated with prolonged survival in patients with high-grade ovarian serous carcinoma.",
author = "Yen, {M. Jim} and Hsu, {Chih Yi} and Mao, {Tsui Lien} and Wu, {Tzyy Choou} and Roden, {Richard S} and Tian-Li Wang and Shih, {Ie Ming}",
year = "2006",
month = "2",
day = "1",
doi = "10.1158/1078-0432.CCR-05-1397",
language = "English (US)",
volume = "12",
pages = "827--831",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "3 I",

}

TY - JOUR

T1 - Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma

AU - Yen, M. Jim

AU - Hsu, Chih Yi

AU - Mao, Tsui Lien

AU - Wu, Tzyy Choou

AU - Roden, Richard S

AU - Wang, Tian-Li

AU - Shih, Ie Ming

PY - 2006/2/1

Y1 - 2006/2/1

N2 - Purpose: Mesothelin is an emerging marker for cancer diagnosis and target-based therapy, yet relatively little is known about the clinical significance of mesothelin expression in tumors. In this study, we correlate mesothelin immunoreactivity to clinicopathologic features in ovarian serous carcinoma. Experimental Design: Mesothelin expression levels were compared among 81 publicly available serial analysis of gene expression (SAGE) libraries of various carcinoma and normal tissue types. Immunohistochemistry using a well-characterized mesothelin monoclonal antibody (5B2) was done to evaluate mesothelin expression in 167 high-grade and 31 low-grade ovarian serous carcinomas. Immunohistochemistry staining scores were correlated with patient survival, tumor site, tumor grade, in vitro drug resistance, and differentiation status of tumor cells. Results: SAGE analysis showed that mesothelin was overexpressed in 50% of ovarian and pancreatic carcinomas but rarely in other cancer types, including liver, colon, kidney, prostate, and breast. Mesothelin immunoreactivity (>5% of tumor cells) was present in 55% of ovarian serous carcinomas with no difference in expression between high-grade and low-grade serous tumors (P = 0.82). Based on Kaplan-Meier analysis, we found that a diffuse mesothelin staining (>50% of tumor cells) in primary high-grade ovarian carcinomas correlated significantly with prolonged survival in patients who had advanced-stage disease and had received optimal debulking surgery followed by chemotherapy (P = 0.023). Mesothelin expression did not correlate significantly with patient age, tumor site, in vitro drug resistance, or tumor differentiation status (P > 0.10). Conclusion: Our results provided new evidence that mesothelin expression is associated with prolonged survival in patients with high-grade ovarian serous carcinoma.

AB - Purpose: Mesothelin is an emerging marker for cancer diagnosis and target-based therapy, yet relatively little is known about the clinical significance of mesothelin expression in tumors. In this study, we correlate mesothelin immunoreactivity to clinicopathologic features in ovarian serous carcinoma. Experimental Design: Mesothelin expression levels were compared among 81 publicly available serial analysis of gene expression (SAGE) libraries of various carcinoma and normal tissue types. Immunohistochemistry using a well-characterized mesothelin monoclonal antibody (5B2) was done to evaluate mesothelin expression in 167 high-grade and 31 low-grade ovarian serous carcinomas. Immunohistochemistry staining scores were correlated with patient survival, tumor site, tumor grade, in vitro drug resistance, and differentiation status of tumor cells. Results: SAGE analysis showed that mesothelin was overexpressed in 50% of ovarian and pancreatic carcinomas but rarely in other cancer types, including liver, colon, kidney, prostate, and breast. Mesothelin immunoreactivity (>5% of tumor cells) was present in 55% of ovarian serous carcinomas with no difference in expression between high-grade and low-grade serous tumors (P = 0.82). Based on Kaplan-Meier analysis, we found that a diffuse mesothelin staining (>50% of tumor cells) in primary high-grade ovarian carcinomas correlated significantly with prolonged survival in patients who had advanced-stage disease and had received optimal debulking surgery followed by chemotherapy (P = 0.023). Mesothelin expression did not correlate significantly with patient age, tumor site, in vitro drug resistance, or tumor differentiation status (P > 0.10). Conclusion: Our results provided new evidence that mesothelin expression is associated with prolonged survival in patients with high-grade ovarian serous carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=32944468551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32944468551&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-05-1397

DO - 10.1158/1078-0432.CCR-05-1397

M3 - Article

VL - 12

SP - 827

EP - 831

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 3 I

ER -